Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1363 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Lan Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, Inc., South Plainfield, NJ, USA. Hauptthemen laut MEDLINE: Biological Availability, Food-Drug Interactions, Pterins, Healthy Volunteers. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Sepiapterin is an orally administered drug in development for the treatment of phenylketonuria, an inborn error of metabolism characterized by the deficiency of the phenylalanine‐metabolizing enzyme phenylalanine hydroxylase. This study characterized the pharmacokinetics, safety, and tolerability of 2 clinical sepiapterin formulations (Phase 1/2, Phase 3) and the effects of food on the pharmacokinetics of the Phase 3 formulation in healthy participants. In Part A, 18 participants were randomized to one of 2 treatment sequences, each with 4 dosing periods comprising a single dose (20 or 60 mg/kg) of the Phase 1/2 or the Phase 3 formulation with a low‐fat diet. In Part B, 14 participants were randomized to one of 2 sequences, each comprising 4 dosing periods of a single dose (20 or 60 mg/kg) of the Phase 3 formulation under fed (high‐fat) or fasted conditions. Following oral administration, sepiapterin was quickly absorbed and rapidly and extensively converted to tetrahydrobiopterin (BH 4 ). BH 4 was the major circulating active moiety. Under low‐fat conditions, the Phase 3 formulation was bioequivalent to the Phase 1/2 formulation at 20 mg/kg, while slightly lower BH 4 exposure (approximately 0.81×) for the Phase 3 formulation was observed at 60 mg/kg. BH 4 exposure increased to approximately 1.7× under the low‐fat condition and approximately 2.8× under the high‐fat condition at a dose of either 20 or 60 mg/kg for the Phase 3 formulation, compared with the fasted condition. Both sepiapterin formulations were well tolerated, with no serious or severe adverse events reported. All treatment‐emergent adverse events were mild or moderate in severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PTC Therapeutics, Inc., South Plainfield, NJ, USA.
Zitieren
APA
Gao, L., Kaushik, D., Xia, Y., Ingalls, K., Milner, S., Smith, N., & Kong, R. (2024). Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1363
Vancouver
Gao L, Kaushik D, Xia Y, Ingalls K, Milner S, Smith N, et al. Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1363
BibTeX
@article{Gao2024,
author = {Gao, Lan and Kaushik, Diksha and Xia, Yi and Ingalls, Kimberly and Milner, Sarah and Smith, Neil and Kong, Ronald},
title = {Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1363}
}
EUVIMED